In This Section      
 

Search Results

A total of 12 matching records were found.

ETCTN10204
A Phase 1b Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO) (ETCTN10204)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J13101
J13101 "A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors".

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17126
EUS-guided gastroenterostomy versus enteral stenting for palliation of malignant gastric outlet obstruction: a randomized clinical trial

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17143
J17143 - A Phase 1 Open-label Dose Escalation and Dose Expansion Study of CGX1321 in Subjects with Advanced Solid Tumors and Phase 1b Study of CGX1321 in Combination with Pembrolizumab in Subjects with Advanced Gastrointestinal Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J17189
J17189-A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients with Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18115
A Phase I Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor (CDAi) with Oral Decitabine in Subjects with Solid Tumors (ASTX727)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18144
Phase 1/2 Dose-Escalation and Expansion Study of FLX475 Alone and in Combination with Pembrolizumab in Advanced Cancer (FLX475-02)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J18161
J18161-ADaptiVe Biomarker Trial that InformS Evolution of Therapy (ADVISE)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1819
Combination ATR and PARP Inhibitor (CAPRI) trial with AZD6738 and olaparib in recurrent ovarian cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1825
A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors (CA224-048)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1928
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects with Advanced Malignancies (TAB001-01)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1989
J1989 - A Phase I, First-In-Human, Multicenter, Open-Label Study of Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore